<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04631770</url>
  </required_header>
  <id_info>
    <org_study_id>E2020306</org_study_id>
    <nct_id>NCT04631770</nct_id>
  </id_info>
  <brief_title>Mediastinal Lymph Node Dissection or Not in Stage I GGN NSCLC</brief_title>
  <official_title>Whether to Perform Mediastinal Lymph Node Disection in Stage I Non-small Cell Lung Cancer With Ground-glass Nodule CT Features</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tianjin Medical University Cancer Institute and Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lung cancer is the leading cause of cancer related death worldwide. Lobectomy or&#xD;
      sub-lobectomy with mediastinal lymph node dissection is the standard surgery. About 50% lung&#xD;
      nodules are pure ground-glass or part-solid nodules. Non-solid nodules rarely develop&#xD;
      mediastinal lymph node metastasis. The present study is a prospective, multicenter and&#xD;
      randomized clinical trial, comparing the overall survival and disease-free survival of&#xD;
      whether performing mediastinal lymph node dissection in non-small cell lung cancer with&#xD;
      ground-glass nodule CT features. The study is a non-inferior statistical comparision, with&#xD;
      681 patients in each group. The anticipated enroll period is 3 years, followed by observation&#xD;
      period of 5 years.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 20, 2020</start_date>
  <completion_date type="Anticipated">October 1, 2028</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Over all sruvival</measure>
    <time_frame>5 years.</time_frame>
    <description>5-year sruvival rate of two groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>5 years</time_frame>
    <description>5-year disease-free survival rate</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">681</enrollment>
  <condition>Lung Neoplasms</condition>
  <condition>Lymph Node Excision</condition>
  <arm_group>
    <arm_group_label>Mediastinal lymph node dissection group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mediastinal lymph node non-dissection group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>B</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Systemic mediastinal lymph node dissection</intervention_name>
    <description>Dissection of at least 3 groups of mediastinal lymph nodes, group 7 must be included.</description>
    <arm_group_label>Mediastinal lymph node dissection group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>No mediastinal lymph node dissection</intervention_name>
    <description>Mediastinal lymph node is not dissection in this group.</description>
    <arm_group_label>Mediastinal lymph node non-dissection group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  No history of malignancies or lung surgery; Diagnosed as NSCLC prior or in lung&#xD;
             surgery; Chest CT shows GGNs with C/T â‰¤ 0.25; Peripheral clinical stage T1N0M0 lung&#xD;
             cancer; No anti-cancer treatment prior to surgery.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non clinical stage T1N0M0 lung cancer; Unable to have complete resection of lung&#xD;
             cancer; Chest CT shows GGNs with C/T &gt; 0.25; History of malignancies; Had any&#xD;
             anti-cancer treatment prior to surgery.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ethics review board of Tianjin Medical University Cancer Institute and Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Dongyan Cheng</last_name>
      <phone>+86-22-23340123</phone>
      <email>chengdongyan916@163.com</email>
    </contact>
    <investigator>
      <last_name>Zhenfa Zhang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chenguang Li, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 15, 2020</study_first_submitted>
  <study_first_submitted_qc>November 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2020</study_first_posted>
  <last_update_submitted>November 15, 2020</last_update_submitted>
  <last_update_submitted_qc>November 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-small cell lung cancer</keyword>
  <keyword>Mediastinal lymph node dissection</keyword>
  <keyword>Ground-glass nodules</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data will be available after publication of the study.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After the follow-up period of the study.</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

